H.R. 2700 · 116th Congress
Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BurgessSponsor44 cosponsors · 44 R
R
Bilirakis
LB
R
Bucshon
SB
R
Brooks
DC
R
Collins
BC
R
Carter
JD
R
Duncan
BF
R
Flores
BG
R
Guthrie
HG
R
Griffith
GG
R
Gianforte
RH
R
Hudson
JH
R
Hill
WH
R
Hurd
BJ
R
Johnson
AK
R
Kinzinger
RL
R
Latta
BL
R
Long
CM
R
McMorris Rodgers
DM
R
McKinley
MM
R
Mullin
PM
R
Mitchell
PO
R
Olson
FS
R
Sensenbrenner
JS
R
Shimkus
SS
R
Scalise
SS
R
Stivers
FU
R
Upton
GW
R
Walden
TW
R
Walberg
MD
R
Diaz-Balart
JH
R
Hagedorn
BL
R
Loudermilk
RM
R
Marshall
ES
R
Stefanik
JH
R
Herrera Beutler
PR
R
Roe
MB
R
Bost
MM
R
Meadows
RW
R
Wittman
DJ
R
Joyce
MA
R
Amodei
AW
R
Wagner
VH
R
Hartzler
DB
R
Bishop29 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act
What it does: CRS summary · Introduced in House · May 14, 2019
Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act
This bill addresses prescription drugs and extends several health care, research, and workforce programs.
Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met.
The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product.
The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing.
The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act
Latest action (Jun 26, 2019): Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Policy area: Health · Origin: House · Introduced: May 14, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.